2019 |
Tsourdi E, Makras P, Rachner TD, Polyzos S, Rauner M, Mandanas S, Hofbauer LC, Anastasilakis AD. Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone. March 2019;120:44-49. |
3 |
3 |
2020 |
Ferrari S, Eastell R, Napoli N, Schwartz A, Hofbauer LC, Chines A, Wang A, Pannacciulli N, Cummings SR. Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone. May 2020;134:115268. |
2 |
0 |
2020 |
Ledesma-Colunga MG, Baschant U, Fiedler IAK, Busse B, Hofbauer LC, Muckenthaler MU, Altamura S, Rauner M. Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. Bone. August 2020;137:115400. |
0 |
0 |
2021 |
Butscheidt S, Tsourdi E, Rolvien T, Delsmann A, Stürznickel J, Barvencik F, Jakob F, Hofbauer LC, Mundlos S, Kornak U, Seefried L, Oheim R. Relevant genetic variants are common in women with pregnancy and lactation-associated osteoporosis (PLO) and predispose to more severe clinical manifestations. Bone. June 2021;147:115911. |
2 |
1 |
2022 |
Rachner TD, Link-Rachner CS, Bornhäuser M, Hofbauer LC. Skeletal health in patients following allogeneic hematopoietic cell transplantation. Bone. May 2022;158:115684. |
0 |
0 |
2022 |
Lademann F, Tsourdi E, Hofbauer LC, Rauner M. Bone cell-specific deletion of thyroid hormone transporter Mct8 distinctly regulates bone volume in young versus adult male mice. Bone. June 2022;159:116375. |
0 |
0 |
2009 |
Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, Gregorio LHd, Hadji P, Hofbauer LC, Álvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. January 2009;24(1):153-161. |
25 |
19 |
2020 |
Hofbauer LC, Rivadeneira F, Westendorf JJ, Civitelli R. Scientific editing in the COVID‐19 era: personal vignettes from the JBMR editors. J Bone Miner Res. June 2020;35(6):1005-1008. |
0 |
0 |
2020 |
Lademann F, Weidner H, Tsourdi E, Kumar R, Rijntjes E, Köhrle J, Hofbauer LC, Rauner M. Disruption of BMP signaling prevents hyperthyroidism‐induced bone loss in male mice. J Bone Miner Res. October 2020;35(10):2058-2069. |
1 |
0 |
2022 |
Wölfel EM, Schmidt FN, vom Scheidt A, Siebels AK, Wulff B, Mushumba H, Ondruschka B, Püschel K, Scheijen J, Schalkwijk CG, Vettorazzi E, Jähn-Rickert K, Gludovatz B, Schaible E, Amling M, Rauner M, Hofbauer LC, Zimmermann EA, Busse B. Dimorphic mechanisms of fragility in diabetes mellitus: the role of reduced collagen fibril deformation. J Bone Miner Res. November 2022;37(11):2259-2276. |
0 |
0 |
2022 |
Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2315-2329. |
5 |
1 |
2023 |
Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, Gagnon C, Palermo A, Marcocci C, Clarke BL, Abbott LG, Hofbauer LC, Kohlmeier L, Pihl S, An X, Eng WF, Smith AR, Ukena J, Sibley CT, Shu AD, Rejnmark L. Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. J Bone Miner Res. January 2023;38(1):14-25. |
0 |
0 |
2023 |
Wölfel EM, Lademann F, Hemmatian H, Blouin S, Messmer P, Hofbauer LC, Busse B, Rauner M, Jähn-Rickert K, Tsourdi E. Reduced bone mass and increased osteocyte tartrate-resistant acid phosphatase (TRAP) activity, but not low mineralized matrix around osteocyte lacunae, are restored after recovery from exogenous hyperthyroidism in male mice. J Bone Miner Res. January 2023;38(1):131-143. |
0 |
0 |
2011 |
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. April 9, 2011;377(9773):1276-1287. |
35 |
35 |
2017 |
Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. November 2017;5(11):898-907. |
26 |
26 |
2016 |
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. NEJM. October 20, 2016;375(16):1532-1543. |
91 |
75 |
2020 |
Thomas T, Casado E, Geusens P, Lems WF, Timoshanko J, Taylor D, Hofbauer LC. Is a treat-to-target strategy in osteoporosis applicable in clinical practice? consensus among a panel of European experts. Osteoporos Int. December 2020;31(12):2303-2311. |
3 |
3 |